NASDAQ$PDSB
PDS Biotechnology Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
PDS Biotech reported financial results and provided a business update.
PDS Biotech reported a net loss of $14.8 million for the year ended December 31, 2020, compared to a net loss of $7.0 million for the previous year. Research and development expenses increased, while general and administrative expenses decreased. The company's cash balance as of December 31, 2020 was $28.8 million.
- Achieved preliminary efficacy benchmark in the Phase 2 combination trial of PDS0101 led by the National Cancer Institute.
- Initiated VERSATILE-002, a Phase 2 trial of lead investigational drug candidate PDS0101, in combination with standard of care KEYTRUDA® for first-line treatment of patients with metastatic or recurrent HPV-positive head and neck cancer.
- Expanded consortium for development of PDS0203, a novel, Versamune®-based second-generation COVID-19 vaccine.
- Received award commitment of up to $60 million from Brazil’s Ministry of Science, Technology and Innovation (MCTI) to fund clinical development and commercialization of PDS0203.
Headline financials
Revenue & EPS history
PDS Biotechnology · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+1.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.0%
Avg return
30 days after
52%
22 / 42 earnings
Positive
+55.0%
Q3 2022
Best reaction
-27.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.1% | +5.7% | -3.8% | |
| Q3 2025 | -12.2% | -18.2% | +1.0% | |
| Q2 2025 | -4.9% | +0.8% | -5.7% | |
| Q1 2025 | +4.8% | +15.0% | +37.8% | |
| Q4 2024 | +0.8% | -12.9% | +0.8% | |
| Q3 2024 | -27.2% | -24.0% | -33.2% | |
| Q2 2024 | -1.0% | +6.6% | +0.0% | |
| Q1 2024 | -0.3% | -4.4% | -21.2% | |
| Q4 2023 | -11.6% | -10.3% | -27.0% | |
| Q3 2023 | +20.3% | +19.7% | +2.9% | |
| Q2 2023 | +21.2% | +17.1% | +13.2% | |
| Q1 2023 | +5.0% | +14.9% | -7.4% | |
| Q4 2022 | +2.2% | -4.7% | +1.0% | |
| Q3 2022 | +55.0% | +54.5% | +64.3% | |
| Q2 2022 | +0.2% | +1.9% | -21.7% | |
| Q1 2022 | -14.3% | +15.2% | -21.7% | |
| Q4 2021 | -1.1% | -1.0% | -12.1% | |
| Q3 2021 | -1.6% | +2.2% | -14.6% | |
| Q2 2021 | +0.6% | -6.5% | +44.5% | |
| Q1 2021 | +8.2% | +27.0% | +174.1% | |
| Q4 2020 | +1.9% | -5.3% | +2.3% | |
| Q3 2020 | -0.5% | -1.9% | +3.8% | |
| Q2 2020 | -5.1% | +0.7% | -26.5% | |
| Q1 2020 | -2.3% | -1.8% | +39.3% | |
| Q4 2019 | +2.3% | -7.9% | +29.6% | |
| Q3 2019 | +0.0% | -14.0% | -3.4% | |
| Q2 2019 | +1.1% | -0.5% | -15.2% | |
| Q1 2019 | +43.0% | +18.6% | +6.4% | |
| Q4 2018 | +3.8% | +2.6% | -1.7% | |
| Q3 2018 | -2.8% | -4.9% | -6.2% | |
| Q2 2018 | +1.3% | +0.0% | -4.3% | |
| Q1 2018 | -6.4% | -3.6% | -15.3% | |
| Q4 2017 | +1.5% | +9.4% | -92.2% | |
| Q3 2017 | +1.2% | -2.2% | -8.0% | |
| Q2 2017 | -1.2% | -3.1% | -2.0% | |
| Q1 2017 | +2.8% | +2.4% | +3.2% | |
| Q4 2016 | -9.5% | -8.8% | -7.1% | |
| Q3 2016 | -6.3% | -0.6% | +9.9% | |
| Q2 2016 | +1.9% | +0.1% | -4.6% | |
| Q1 2016 | -4.2% | — | — | |
| Q4 2015 | -14.2% | — | — | |
| Q3 2015 | +0.5% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro